title: Drug advances in inflammatory bowel disease.
abstract: The pathogenesis of inflammatory bowel disease (IBD) remains incompletely understood, but is thought to be a consequence of immune dysregulation, impaired mucosal integrity, enteric bacterial dysbiosis and genetic susceptibility factors. Recent drug advances in the treatment of IBD have clarified the role of existing medication, including 5-amino-salicylic acids (5-ASAs) and has seen a burgeoning use of treatment with biologicals. With recent advances in our understanding of these debilitating diseases, it is hoped that novel therapeutic targets can be identified.
authors.affiliation: Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK.
authors.forename: R Alexander
authors.initials: RA
authors.lastname: Speight
authors.forename: John C
authors.initials: JC
authors.lastname: Mansfield
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000890:Anti-Infective Agents; D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha
keywords: 5-amino-salicylic acid; Crohn’s disease; anti-TNFα; deep remission; ulcerative colitis
references.citation: Arthritis Rheum. 2007 Sep;56(9):2896-904
references.pmid: 17763441
references.citation: N Engl J Med. 2010 Apr 15;362(15):1383-95
references.pmid: 20393175
references.citation: Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543
references.pmid: 23076889
references.citation: Clin Gastroenterol Hepatol. 2007 Jan;5(1):95-102
references.pmid: 17234558
references.citation: Gastroenterology. 2009 Dec;137(6):1934-43.e1-3
references.pmid: 19766640
references.citation: Am J Gastroenterol. 2010 Feb;105(2):289-97
references.pmid: 19861953
references.citation: Gut. 2010 Sep;59(9):1200-6
references.pmid: 20650924
references.citation: Ann Rheum Dis. 2013 Apr;72(4):517-24
references.pmid: 22562972
references.citation: Can J Gastroenterol. 2007 Dec;21(12):827-34
references.pmid: 18080055
references.citation: Gastroenterology. 2006 Feb;130(2):323-33; quiz 591
references.pmid: 16472588
references.citation: Inflamm Bowel Dis. 2000 Feb;6(1):8-15
references.pmid: 10701144
references.citation: Rheumatology (Oxford). 2010 Nov;49(11):2217-9
references.pmid: 20837498
references.citation: Lancet. 2008 Feb 23;371(9613):660-667
references.pmid: 18295023
references.citation: Gut. 2012 Jun;61(6):918-32
references.pmid: 22115827
references.citation: Gut. 2009 Apr;58(4):501-8
references.pmid: 18832524
references.citation: Lancet. 2009 Nov 7;374(9701):1617-25
references.pmid: 19837455
references.citation: Clin Gastroenterol Hepatol. 2003 Jan;1(1):36-43
references.pmid: 15017515
references.citation: Lancet. 2012 Dec 1;380(9857):1909-15
references.pmid: 23063316
references.citation: Aliment Pharmacol Ther. 2006 Apr 1;23(7):841-55
references.pmid: 16573787
references.citation: Gut. 2005 Jul;54(7):960-5
references.pmid: 15951542
references.citation: Gut. 2009 Apr;58(4):492-500
references.pmid: 18832518
references.citation: Aliment Pharmacol Ther. 2003 Aug 1;18(3):263-77
references.pmid: 12895211
references.citation: Lancet. 2002 May 4;359(9317):1541-9
references.pmid: 12047962
references.citation: Aliment Pharmacol Ther. 1999 Nov;13(11):1413-7
references.pmid: 10571596
references.citation: N Engl J Med. 2005 Dec 8;353(23):2462-76
references.pmid: 16339095
references.citation: Inflamm Bowel Dis. 2011 Jun;17(6):1415-22
references.pmid: 21560202
references.citation: Clin Gastroenterol Hepatol. 2011 Jan;9(1):36-41.e1
references.pmid: 20888436
references.citation: Gastroenterology. 2004 Feb;126(2):402-13
references.pmid: 14762776
references.citation: Gastroenterology. 2007 Jan;132(1):66-75; quiz 432-3
references.pmid: 17241860